Course: Understanding Cost-Effectiveness Analysis in Health Care

  • Course Home
  • Syllabus
  • Schedule
  • Lecture Materials
  • Readings
  • Assignments
  • Want to stay in touch?

    2 + 4 =  


Reading List (21KB) This document contains a comprehensive list of all readings, including those for the live chat sessions.


Haddix AC, Teutsch SM, Corso PS (eds). Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation: Second Edition. 2002. Oxford University Press.

Session Topic Readings
Module 1: Core Concepts


Economics Concepts Overview

Phillips KA, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002; 22(2): 98-105.

Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS; Cost Work Group, Third US Preventive Services Task Force. The art and science of incorporating
cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med. 2001; 20(3 Suppl): 36-43.


Recommendations of the Panel on Cost-Effectiveness in Health and Medicine

Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002; 94(4): 291-7.

Ramsey SD, Kessler LG. Does economics matter when treating advanced non-small cell lung cancer? Oncologist. 2002; 7(3): 179-80.

Roberts TG Jr, Lynch TJ Jr, Chabner BA. Choosing chemotherapy for lung cancer based on cost: not yet. Oncologist. 2002; 7(3): 177-8.


Decision Rules

Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Costeffectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002; 162(21): 2478-86.

Module 2: Quality Adjusted Life Years


Quality Adjusted Life Years

Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003; 289(3): 313-22.

Module 3: Costs and Calculations


Measuring Cost Over Time

Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, Matchar DB. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999; 52(3): 259-71.


Multiple Year Cost Calculations

Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000; 283(11): 1460-8.

Module 4: Putting It All Together


Putting It All Together (with examples from the readings)

Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002; 137(4): 225-31.